Neos Therapeutics (NASDAQ: NEOS) and Innocoll (NASDAQ:INNL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Institutional & Insider Ownership
46.0% of Neos Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Innocoll shares are owned by institutional investors. 5.2% of Neos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Neos Therapeutics and Innocoll’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Neos Therapeutics and Innocoll’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neos Therapeutics||$9.15 million||29.32||-$83.33 million||($3.42)||-2.70|
Innocoll has lower revenue, but higher earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than Innocoll, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations for Neos Therapeutics and Innocoll, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neos Therapeutics currently has a consensus price target of $16.20, suggesting a potential upside of 75.14%. Innocoll has a consensus price target of $3.00, suggesting a potential upside of 27.66%. Given Neos Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Neos Therapeutics is more favorable than Innocoll.
Neos Therapeutics beats Innocoll on 8 of the 11 factors compared between the two stocks.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.